FDA approves Resmetirom, the first NASH liver disease treatment by Madrigal Pharmaceuticals.

The US FDA has approved Madrigal Pharmaceuticals' drug Resmetirom as the first treatment for non-alcoholic steatohepatitis (NASH) liver disease. NASH, linked to obesity and diabetes, can cause liver scarring and increase the risk of liver cancer and liver transplantation. Resmetirom, granted Orphan Drug status, reduces liver fat accumulation and is the first treatment to reverse liver fibrosis.